By Kao Shih-ching / Staff reporterTaiMed Biologics Inc (中裕新藥) yesterday dismissed speculation that it is having financial difficulties because of declining sales of its Trogarzo HIV treatment in the US. “Chang shared why sales were weaker than expected, but he also said he was upbeat that sales would improve next year. However, rumors surfaced the next day — that TaiMed is facing financial trouble or that it is bound to shut down,” TaiMed chief financial officer Jack Chen (陳怡成) told the Taipei Times by telephone. “It would take time for sales to boom as our drug is new and a fourth-line treatment,” Chen said, adding that sales are expected to improve next year. TaiMed has free cash flow of more than NT$1.6 billion and gross margin improved to 40 percent last quarter, he said.

Source: Taipei Times December 19, 2019 15:56 UTC